Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden-Reference-Cited by-同舟云学术

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

Published:2005 Issue:7 Volume:52 Page:1986-1992
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Askling Johan,Fored C. Michael,Brandt Lena,Baecklund Eva,Bertilsson Lennart,Cöster Lars,Geborek Pierre,Jacobsson Lennart T.,Lindblad Staffan,Lysholm Jörgen,Rantapää-Dahlqvist Solbritt,Saxne Tore,Romanus Victoria,Klareskog Lars,Feltelius Nils

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference21 articles.

1. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

2. Safety of Tumour Necrosis Factor-?? Antagonists

3. Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

4. Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor

Cited by 353 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?;PLOS ONE;2024-07-03

2. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy;Journal of Infection and Public Health;2024-06

3. The Saudi consensus recommendations for the management of psoriatic arthritis (2023);Clinical Rheumatology;2024-01-13

4. Analysis of Risk Factors for Developing Tuberculosis in Patients Who Received Prophylactic Latent Tuberculosis Infection Treatment with Experience of Biologic Medications;Biological and Pharmaceutical Bulletin;2023-12-01

5. Lungentuberkulose unter Therapie mit Tocilizumab/Etanercept;Aktuelle Rheumatologie;2023-10-04